{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atrophy%2C+Muscular&page=7",
    "query": {
      "condition": "Atrophy, Muscular",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 847,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atrophy%2C+Muscular&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atrophy%2C+Muscular&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T08:46:29.134Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07105371",
      "title": "Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Motor Disorders"
      ],
      "interventions": [
        {
          "name": "Exosome Secretome",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Foundation for Orthopaedics and Regenerative Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2024-07-14",
      "completion_date": "2026-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Naples, Florida",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105371"
    },
    {
      "nct_id": "NCT01417364",
      "title": "The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sarcopenia"
      ],
      "interventions": [
        {
          "name": "Testosterone enanthate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "60 Years to 75 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2016-01",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-02",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01417364"
    },
    {
      "nct_id": "NCT03362502",
      "title": "A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "PF-06939926",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "4 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2018-01-23",
      "completion_date": "2025-07-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 22,
      "location_summary": "Los Angeles, California • Durham, North Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03362502"
    },
    {
      "nct_id": "NCT00661453",
      "title": "CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Spinal Muscular Atrophy Type I"
      ],
      "interventions": [
        {
          "name": "Valproic Acid and Levocarnitine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "2 Weeks to 12 Months"
      },
      "enrollment_count": 40,
      "start_date": "2008-04",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2015-06-15",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • Durham, North Carolina + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00661453"
    },
    {
      "nct_id": "NCT07608432",
      "title": "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophy (DMD)",
        "DMD",
        "Muscular Dystrophies",
        "Muscular Dystrophy in Children",
        "Muscular Dystrophy, Duchenne Type",
        "Muscular Dystrophy, Duchenne and Becker Types",
        "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)",
        "Genetic Disease, Inborn",
        "Genetic Disease, X-Linked",
        "Congenital, Hereditary, and Neonatal Diseases and Abnormalities",
        "Neuromuscular Diseases (NMD)"
      ],
      "interventions": [
        {
          "name": "Zeleciment Rostudirsen (DYNE-251)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dyne Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "4 Years to 18 Years · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2026-06",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Hillsborough, North Carolina",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07608432"
    },
    {
      "nct_id": "NCT02367092",
      "title": "Exercise Intervention in Liver Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "End Stage Liver Disease",
        "Sarcopenia",
        "Liver Cirrhoses"
      ],
      "interventions": [
        {
          "name": "Exercise Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2016-07",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2022-09-07",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02367092"
    },
    {
      "nct_id": "NCT04357184",
      "title": "BFRT for Severe Lower Extremity Muscle Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Severe Muscle Atrophy",
        "Muscle Weakness"
      ],
      "interventions": [
        {
          "name": "Blood flow restriction training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Cincinnati Sportsmedicine Research and Education Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2020-04-14",
      "completion_date": "2022-02-15",
      "has_results": false,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04357184"
    },
    {
      "nct_id": "NCT03867435",
      "title": "Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type-1",
        "Myotonic Dystrophy Type-2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "11 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-02-24",
      "completion_date": "2021-11-02",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867435"
    },
    {
      "nct_id": "NCT05326633",
      "title": "Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Critical Illness",
        "Sarcopenia",
        "ICU Acquired Weakness"
      ],
      "interventions": [
        {
          "name": "MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "60 Years to 99 Years"
      },
      "enrollment_count": 78,
      "start_date": "2027-03-01",
      "completion_date": "2029-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05326633"
    },
    {
      "nct_id": "NCT03123913",
      "title": "Study of Testosterone and rHGH in FSHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Testosterone Enanthate",
          "type": "DRUG"
        },
        {
          "name": "Somatropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2017-12-18",
      "completion_date": "2022-03-28",
      "has_results": true,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-10-23T08:46:29.134Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03123913"
    }
  ]
}